Kyoung Min Kim1,2, Usama Khamis Hussein1,3, See-Hyoung Park4, Young Jae Moon2,5, Zhongkai Zhang6, Asmaa Gamal Ahmed1,7, Ae-Ri Ahn1,2, Ho Sung Park1,2, Jung Ryul Kim8,9, Kyu Yun Jang10,11. 1. Department of Pathology, Jeonbuk National University Medical School, 567 Baekje-daero, Dukjin-gu, Jeonju, 54896, Republic of Korea. 2. Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical, Research Institute of Jeonbuk National University Hospital and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea. 3. Faculty of Science, Beni-Suef University, Beni-Suef, Egypt. 4. Department of Bio and Chemical Engineering, Hongik University, Sejong, Republic of Korea. 5. Department of Biochemistry and Molecular Biology, Jeonbuk National University Medical School, Jeonju, Republic of Korea. 6. Department of Orthopedic Surgery, Jeonbuk National University Medical School, 567 Baekje-daero, Dukjin-gu, Jeonju, 54896, Republic of Korea. 7. Faculty of Postgraduate Studies and Advanced Sciences, Beni-Suef University, Beni-Suef, Egypt. 8. Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical, Research Institute of Jeonbuk National University Hospital and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea. jrkeem@jbnu.ac.kr. 9. Department of Orthopedic Surgery, Jeonbuk National University Medical School, 567 Baekje-daero, Dukjin-gu, Jeonju, 54896, Republic of Korea. jrkeem@jbnu.ac.kr. 10. Department of Pathology, Jeonbuk National University Medical School, 567 Baekje-daero, Dukjin-gu, Jeonju, 54896, Republic of Korea. kyjang@jbnu.ac.kr. 11. Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical, Research Institute of Jeonbuk National University Hospital and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea. kyjang@jbnu.ac.kr.
Abstract
BACKGROUND: IL4Rα and IL13Rα1 are constituents of the type II IL4 receptor. Recently, IL4Rα and IL13Rα1 were reported to have roles in cancer progression and suggested as potential prognostic markers. However, studies on IL4Rα and IL13Rα1 in soft-tissue sarcomas have been limited. METHODS: This study investigated the immunohistochemical expression of IL4Rα and IL13Rα1 in 89 soft-tissue sarcomas of the extremities, superficial trunk, and retroperitoneum. Immunohistochemical staining for IL4Rα and IL13Rα1 were scored according to a combination of staining intensity and staining area in tissue microarray samples. Positivity for the immunohistochemical expression of IL4Rα and IL13Rα1 were determined using receiver operating curve analysis. Statistical analysis was performed using regression analysis and a chi-square test. RESULTS: In human soft-tissue sarcomas, immunohistochemical expression of IL4Rα was significantly associated with IL13Rα1 expression. Nuclear and cytoplasmic expression of IL4Rα and IL13Rα1 were significantly associated with shorter survival of soft-tissue sarcoma patients in univariate analysis. Multivariate analysis indicated that nuclear expression of IL4Rα and IL13Rα1 were independent indicators of shorter overall survival (IL4Rα; p = 0.002, IL13Rα1; p = 0.016) and relapse-free survival (IL4Rα; p = 0.022, IL13Rα1; p < 0.001) of soft-tissue sarcoma patients. Moreover, the co-expression pattern of nuclear IL4Rα and IL13Rα1 was an independent indicator of shorter survival of soft-tissue sarcoma patients (overall survival; overall p < 0.001, relapse-free survival; overall p < 0.001). CONCLUSIONS: This study suggests IL4Rα and IL13Rα1 are associated with the progression of soft-tissue sarcoma, and the expression of IL4Rα and IL13Rα1 might be novel prognostic indicators of soft-tissue sarcoma patients.
BACKGROUND:IL4Rα and IL13Rα1 are constituents of the type II IL4 receptor. Recently, IL4Rα and IL13Rα1 were reported to have roles in cancer progression and suggested as potential prognostic markers. However, studies on IL4Rα and IL13Rα1 in soft-tissue sarcomas have been limited. METHODS: This study investigated the immunohistochemical expression of IL4Rα and IL13Rα1 in 89 soft-tissue sarcomas of the extremities, superficial trunk, and retroperitoneum. Immunohistochemical staining for IL4Rα and IL13Rα1 were scored according to a combination of staining intensity and staining area in tissue microarray samples. Positivity for the immunohistochemical expression of IL4Rα and IL13Rα1 were determined using receiver operating curve analysis. Statistical analysis was performed using regression analysis and a chi-square test. RESULTS: In human soft-tissue sarcomas, immunohistochemical expression of IL4Rα was significantly associated with IL13Rα1 expression. Nuclear and cytoplasmic expression of IL4Rα and IL13Rα1 were significantly associated with shorter survival of soft-tissue sarcomapatients in univariate analysis. Multivariate analysis indicated that nuclear expression of IL4Rα and IL13Rα1 were independent indicators of shorter overall survival (IL4Rα; p = 0.002, IL13Rα1; p = 0.016) and relapse-free survival (IL4Rα; p = 0.022, IL13Rα1; p < 0.001) of soft-tissue sarcomapatients. Moreover, the co-expression pattern of nuclear IL4Rα and IL13Rα1 was an independent indicator of shorter survival of soft-tissue sarcomapatients (overall survival; overall p < 0.001, relapse-free survival; overall p < 0.001). CONCLUSIONS: This study suggests IL4Rα and IL13Rα1 are associated with the progression of soft-tissue sarcoma, and the expression of IL4Rα and IL13Rα1 might be novel prognostic indicators of soft-tissue sarcomapatients.
Authors: Bryan M Burt; Andrew Bader; Daniel Winter; Scott J Rodig; Raphael Bueno; David J Sugarbaker Journal: Clin Cancer Res Date: 2012-01-18 Impact factor: 12.531
Authors: Sherry L LaPorte; Z Sean Juo; Jana Vaclavikova; Leremy A Colf; Xiulan Qi; Nicola M Heller; Achsah D Keegan; K Christopher Garcia Journal: Cell Date: 2008-01-25 Impact factor: 41.582